| Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon Cancers 11 (11), 1756, 2019 | 132 | 2019 |
| Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors VYS Oei, M Siernicka, A Graczyk-Jarzynka, HJ Hoel, W Yang, D Palacios, ... Cancer immunology research 6 (4), 467-480, 2018 | 98 | 2018 |
| Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer PC O’Leary, M Terrile, M Bajor, P Gaj, BT Hennessy, GB Mills, ... Breast Cancer Research 16, 1-15, 2014 | 69 | 2014 |
| Maintenance of long‐term potentiation in hippocampal mossy fiber—CA3 pathway requires fine‐tuned MMP‐9 proteolytic activity G Wiera, G Wozniak, M Bajor, L Kaczmarek, JW Mozrzymas Hippocampus 23 (6), 529-543, 2013 | 68 | 2013 |
| Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents M Bajor, AO Zych, A Graczyk-Jarzynka, A Muchowicz, M Firczuk, ... British Journal of Cancer 119 (7), 873-884, 2018 | 56 | 2018 |
| Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma A Trzeciecka, S Klossowski, M Bajor, R Zagozdzon, P Gaj, A Muchowicz, ... Oncotarget 7 (2), 1717, 2015 | 56 | 2015 |
| PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress M Klopotowska, M Bajor, A Graczyk-Jarzynka, A Kraft, Z Pilch, A Zhylko, ... Cancer immunology research 10 (2), 228-244, 2022 | 48 | 2022 |
| The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance K Retecki, M Seweryn, A Graczyk-Jarzynka, M Bajor Cancers 13 (23), 6012, 2021 | 48 | 2021 |
| Proteolytic remodeling of the synaptic cell adhesion molecules (CAMs) by metzincins in synaptic plasticity M Bajor, L Kaczmarek Neurochemical research 38, 1113-1121, 2013 | 45 | 2013 |
| Synaptic cell adhesion molecule‐2 and collapsin response mediator protein‐2 are novel members of the matrix metalloproteinase‐9 degradome M Bajor, P Michaluk, P Gulyassy, AK Kekesi, G Juhasz, L Kaczmarek Journal of neurochemistry 122 (4), 775-788, 2012 | 45 | 2012 |
| Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate A Graczyk-Jarzynka, A Goral, A Muchowicz, R Zagozdzon, M Winiarska, ... Redox biology 21, 101062, 2019 | 40 | 2019 |
| PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells M Bajor, A Graczyk-Jarzynka, K Marhelava, A Burdzinska, A Muchowicz, ... Journal for Immunotherapy of Cancer 10 (1), 2022 | 38 | 2022 |
| Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy M Firczuk, M Bajor, A Graczyk-Jarzynka, K Fidyt, A Goral, R Zagozdzon Cancer letters 471, 1-11, 2020 | 35 | 2020 |
| Complement components, proteolysis‑related, and cell communication‑related proteins detected in urine proteomics are associated with IgA nephropathy. K Mucha, M Bakun, R Jazwiec, M Dadlez, M Florczak, M Bajor, K Gala, ... Polish archives of internal medicine 124 (7-8), 380-38, 2014 | 34 | 2014 |
| Triple combination of ascorbate, menadione and the inhibition of peroxiredoxin-1 produces synergistic cytotoxic effects in triple-negative breast cancer cells M Bajor, A Graczyk-Jarzynka, K Marhelava, M Kurkowiak, A Rahman, ... Antioxidants 9 (4), 320, 2020 | 26 | 2020 |
| Application of genome editing techniques in immunology AO Zych, M Bajor, R Zagozdzon Archivum Immunologiae et Therapiae Experimentalis 66, 289-298, 2018 | 23 | 2018 |
| Adenanthin, a new inhibitor of thiol‐dependent antioxidant enzymes, impairs the effector functions of human natural killer cells M Siernicka, M Winiarska, M Bajor, M Firczuk, A Muchowicz, M Bobrowicz, ... Immunology 146 (1), 173-183, 2015 | 22 | 2015 |
| An interplay of S-nitrosylation and metal ion binding for astrocytic S100B protein M Bajor, M Zaręba-Kozioł, L Zhukova, K Goryca, J Poznański, ... PLoS One 11 (5), e0154822, 2016 | 19 | 2016 |
| Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel) 11 (11) K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon | 10 | 2019 |
| Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells J Chlebowska-Tuz, O Sokolowska, P Gaj, M Lazniewski, M Firczuk, ... haematologica 103 (11), 1843, 2018 | 10 | 2018 |
